Company News
Sun Pharma LIB Therapeutics Lerodalcibep Global Licensing Agreement
Sun Pharma and LIB Therapeutics sign exclusive global licensing agreement for PCSK9 inhibitor lerodalcibep, excluding US and China.
Lerodalcibep received EU approval as Lyrokaul on September 21, 2026,
